Imunon’s 5% Rally Masks Deep Structural Weakness, Exposes Biotech Risk
Imunon’s 5.04% rally masks deep weakness—price below its 200‑day average, thin liquidity, and a sector‑wide decline. Investors should tread carefully.
2 minutes to read
IMUNON INC
Imunon Shares Jump 17.8% After Strategic Partnership With VoxelDox Revealed
Imunon’s shares jump 17.8% after announcing a strategic partnership with VoxelDox to sell ThermoDox, boosting future revenue potential and supporting its ovarian‑cancer trial.
3 minutes to read